ZHEJIANG CONBA PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.93 CNY | +0.61% |
|
-0.40% | -2.38% |
| Sales 2024 * | 7.76B 1.07B | Sales 2025 * | 9.02B 1.24B | Capitalization | 12.67B 1.75B |
|---|---|---|---|---|---|
| Net income 2024 * | 782M 108M | Net income 2025 * | 927M 128M | EV / Sales 2024 * | 1.63 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.41 x |
| P/E ratio 2024 * |
16.1
x | P/E ratio 2025 * |
13.6
x | Employees | 8,415 |
| Yield 2024 * |
2.84% | Yield 2025 * |
3.14% | Free-Float | 59.66% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.61% | ||
| 1 week | -0.40% | ||
| Current month | +2.07% | ||
| 1 month | +1.02% | ||
| 3 months | +14.12% | ||
| 6 months | +1.65% | ||
| Current year | -2.38% |
1 week
4.84
5.16
1 month
4.745.16
Current year
4.075.29
1 year
4.077.44
3 years
3.837.44
5 years
3.839.26
10 years
3.8313.19
| Managers | Title | Age | Since |
|---|---|---|---|
Guo Liang Luo
PSD | President | 62 | 20-07-21 |
Ming Chen
DFI | Director of Finance/CFO | 48 | 20-07-21 |
Zhen Xian Yuan
BRD | Director/Board Member | 48 | 18-04-25 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ji Qiang Hu
CHM | Chairman | 63 | 05-04-28 |
Ming Chen
DFI | Director of Finance/CFO | 48 | 20-07-21 |
Zuo Jun Dong
BRD | Director/Board Member | 54 | 20-07-21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 117 M€ | +0.83% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 4.93 | +0.61% | 26,054,140 |
| 24-04-22 | 4.9 | -2.78% | 56,507,810 |
| 24-04-19 | 5.04 | +0.40% | 35,374,610 |
| 24-04-18 | 5.02 | -1.18% | 52,014,690 |
| 24-04-17 | 5.08 | +2.63% | 60,394,050 |
End-of-day quote Shanghai S.E., April 22, 2024
More quotes
Zhejiang CONBA Pharmaceutical Co Ltd is a China-based company, principally engaged in the research and development, manufacture and distribution of traditional Chinese medicines, modern phytomedicines and chemical drugs. The Company also provides active ingredients. The Company's products include tablets, capsules, pills, granules, powders, injections, oral solutions, syrups, eye drops, nasal drops, ear drops, ointments and others. Its products are applied in cardiovascular and cerebrovascular diseases, urinary system diseases, digestive diseases, respiratory diseases, endocrine system, nervous system, anti-infection and other treatment areas. The Company also provides value-added services. The Company distributes its products within domestic markets.
Sector
Pharmaceuticals
Calendar
2024-04-26
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
4.93
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.38% | 1.74B | |
| +17.88% | 44.31B | |
| +20.02% | 22.17B | |
| +13.05% | 14.62B | |
| +8.06% | 13.12B | |
| +39.21% | 11.58B | |
| -8.33% | 6.96B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +5.03% | 5.03B |
- Stock Market
- Equities
- 600572 Stock
